Navigation Links
Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Report Fourth Quarter and Fiscal-Year 2008 Results
Date:2/13/2009

ation technology systems we have been implementing during the past several years are enabling us to focus our efforts on our most expensive care delivery areas in ways that both improve care and help us achieve our goal of price trends that are below those of our competitors. We believe the market will value a lower rate of price increases," added Halvorson.

"We continue to follow the financial markets closely and are preparing for additional headwinds," said Executive Vice President and Chief Financial Officer Kathy Lancaster. "With uncertainty lingering in the markets, we are poised to take appropriate actions that limit losses and position us to participate in market recoveries. In addition, we continue to hold a highly diversified and liquid portfolio of investments, which we have marked down to current market values for financial reporting purposes. Over the long run, our portfolio has performed well, and we believe that our investment strategy will meet our long-term goals."

Capital spending in the fourth quarter was nearly $1.1 billion, on par with the fourth quarter of 2007. Similarly, capital spending in 2008 reached $2.9 billion, slightly more than the $2.8 billion reported in 2007. During the past year, KFHP/H opened three new hospitals, a hospital tower, and 10 medical office buildings to meet the needs of members. In 2009, KFHP/H will reduce or defer some capital projects and adjust project timelines where it is prudent to do so.

"During the past several years, we have significantly enhanced our care delivery infrastructure, including our information systems, facilities, and medical technology. These enhancements give our physicians, nurses, labor partners, and other employees the ability to strengthen the quality of our care and service, and manage costs. Capitalizing on our integrated system while making progress with the continuing roll-out of our systems infrastructure will h
'/>"/>

SOURCE Kaiser Permanente
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Kaiser Permanente Approves $43 Million in Community Benefit Grants in Fourth Quarter 2008
2. Kaiser Permanente Provides Seed Funding to the Institute for Healthcare Improvements New Open School for Health Professions
3. Kaiser Family Foundation Partners With Media Around The Globe to Address HIV/AIDS
4. Kaiser Permanente Receives the Most Stars in California Office of Patient Advocates Annual Quality Report Card
5. U.S. News & World Report Names Kaiser Permanente Top-Ranked Health Plan in Georgia
6. Audio: Kaiser Permanente is Colorados Top Commercial and Medicare Plan on U.S. News & World Report/NCQA Americas Best Health Plans List
7. Kaiser Permanente Honored for Success in Diabetes and Heart Disease Prevention
8. Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results
9. Kaiser Family Foundation to Launch Non-Profit Health Policy News Service
10. Kaiser Permanente Approves $12 Million in Community Benefit Grants in Third Quarter of 2008
11. Kaiser Permanente and Veterans Affairs Preview Electronic Health Record Interoperability to Enable Better Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... presented today at the annual meeting of the Radiological ... evidence of the benefit of annual screening ultrasound for ... for breast cancer. In addition, the study confirmed that ... "We found that annual screening with ultrasound in ...
... ... transplant center and the first for Chicago’s south and southwest suburbs, following formal approval ... Review Board. , ... Springfield, Ill. (Vocus) -- Advocate Christ Medical Center in Oak Lawn, Ill. ...
... ... announces that a new market research report ... The Future of Central Nervous System Diseases ... Benchmarking, Product Pipeline and Deals Analysis ...
... , NEW YORK, ... market research report is available in its catalogue: ... Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline ... , Summary , The author ...
... The Kerlan Jobe Orthopaedic Clinic, a sports medicine clinic in ... million to settle allegations that it received illegal kickbacks from ... , The settlement resolves allegations that HealthSouth paid ... grants, donations to the Kerlan Jobe Foundation, loan forgiveness on ...
... Ky., Dec. 1 A scientist who broadened the understanding ... control and relieve it -- has won the 2010 University ... professor emeritus at McGill University in Montreal, was selected for ... not at the point of injury but instead in their ...
Cached Medicine News:Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 1, 2011 Novartis Pharmaceuticals Corporation ("Novartis") will showcase ... and investigational agents at the 47th Annual Meeting of ... underscore the company,s commitment to developing treatments to improve ... our commitment to R&D and collaborations with the scientific ...
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... presenting at the Jefferies 2011 Global Healthcare Conference in New ... on Tuesday, June 7, 2011 at 11:00 a.m. Eastern Time ... and may be accessed on the Company,s website at ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18